Glucotrack, Inc.

Glucotrack, Inc. announced the completion of its strategic business combination with Lōkahi Therapeutics, establishing a publicly listed platform for healthcare asset identification and advancement. Lōkahi Therapeutics will become the operating and controlling business, with its securityholders expected to hold approximately 90% of the combined company on a fully diluted basis. A planned private placement financing will support the combined entity, while Glucotrack's legacy continuous blood glucose monitoring (CBGM) business will operate as a wholly owned, separate subsidiary. Erik Emerson has been appointed CEO of the combined company, and Paul Goode will serve as CTO and CEO of the CBGM subsidiary.

Glucotrack, Inc. received two separate notices from Nasdaq regarding non-compliance with listing rules. The first, on May 11, 2026, cited failure to maintain a minimum bid price of $1.00 per share. The second, on May 15, 2026, indicated the company no longer meets the $2,500,000 minimum stockholders' equity requirement, nor its alternatives. Glucotrack intends to request a hearing by May 18, 2026, to appeal these delisting determinations, which will stay further delisting actions.

Glucotrack, Inc. submitted an Investigational Device Exemption (IDE) application to the U.S. FDA for a U.S. clinical study of its implantable continuous blood glucose monitor (CBGM) technology, marking a significant regulatory milestone. For the first quarter of 2026, the company reported a net loss of $4.33 million, an improvement from $6.83 million in Q1 2025. However, cash and cash equivalents decreased to $3.93 million from $7.38 million at year-end 2025, and management raised substantial doubt about the company's ability to continue as a going concern due to accumulated deficits and negative cash flow.

Glucotrack, Inc. reported its first quarter 2026 financial results, alongside significant progress in its continuous blood glucose monitoring (CBGM) program. The company submitted an Investigational Device Exemption (IDE) application to the FDA for its fully implantable CBGM technology and aims to initiate U.S. clinical studies in the second half of 2026. Financially, Glucotrack reduced its net loss to $4.3 million from $6.8 million year-over-year and strengthened its balance sheet by reducing debt. However, cash and cash equivalents decreased to $3.9 million, providing a runway into early Q3 2026.

Glucotrack, Inc. announced the submission of its Investigational Device Exemption (IDE) application to the U.S. FDA to initiate a U.S. clinical study for its fully implantable continuous blood glucose monitoring (CBGM) technology, targeting a launch in the second half of 2026. This milestone is supported by positive preclinical and in-vitro data published in peer-reviewed journals, demonstrating long-term sensor stability and accuracy. For Q1 2026, the company reported a reduced net loss of $4.3 million and strengthened its balance sheet by cutting debt and extending its financial runway.

Glucotrack, Inc. announced the submission of its Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) for its fully implantable continuous blood glucose monitoring (CBGM) technology. This represents a significant step towards initiating a US clinical study for the device, which aims to provide long-term, real-time, blood-based glucose accuracy without an on-body wearable. The company plans to advance its implantable monitoring system into clinical evaluation in the United States following FDA review and approval, offering a discreet and comfortable solution for people with diabetes.

Glucotrack, Inc. entered into an Exchange Agreement with an investor to convert a portion of an existing promissory note into common stock. A new $988,000 promissory note was partitioned from the original $3,600,000 note and subsequently exchanged for 1,300,000 shares of the company's common stock, with no additional cash consideration from the investor. The issuance of shares is subject to a beneficial ownership limitation of 19.9%. Additionally, the company released an updated investor presentation.

Glucotrack, Inc. announced the publication of a peer-reviewed scientific article in The Journal of Diabetes Research, detailing the long-term accuracy and stability of its fully implantable continuous blood glucose monitoring (CBGM) system. The study, conducted in an ovine model, demonstrated a weighted average Mean Absolute Relative Difference (MARD) of 6.8% over periods of up to 240 days, with no device-related adverse safety events. This externally validated evidence reinforces the company's confidence in the CBGM platform and supports its continued progression towards an IDE submission with the FDA for further clinical development and eventual commercialization.

Glucotrack, Inc. entered into an Exchange Agreement with an investor to convert a portion of an existing promissory note into common stock. The company partitioned a $600,000 promissory note from a larger $3.6 million note. This $600,000 note was then exchanged for 895,000 shares of Glucotrack's common stock, effectively converting debt into equity. The share issuance is subject to a 19.9% beneficial ownership limitation for the investor.

Glucotrack, Inc. entered into an Exchange Agreement to convert a portion of an existing $3.6 million promissory note. The company partitioned a $600,000 note from the original and exchanged it for 895,000 shares of its common stock. This transaction reduces the company's debt while resulting in equity dilution, subject to a 19.9% beneficial ownership limitation for the investor.